US Patent Issued to CRISPR THERAPEUTICS on Sept. 22 for "Methods for manufacturing genetically engineered CAR-T cells" (Massachusetts Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,742,184, issued on Sept. 22, was assigned to CRISPR THERAPEUTICS AG (Zug, Switzerland).

"Methods for manufacturing genetically engineered CAR-T cells" was invented by Hui Yu (Cambridge, Mass.), Mary-Lee Dequeant (Cambridge, Mass.), Demetrios Kalaitzidis (Cambridge, Mass.) and Mohammed Ghonime (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR), such as a CAR that binds human CD19, BCMA, or CD70, and having multiple additional gene edits, for example, a disrupted Regnase-1 gene, a disrupted TGFBRII gene, a disrupted TRAC gene, a disrupted B...